Your Yourlocation: Home > Investigate of tiotropium bromide(136310-93-5) on lung function in current smokers and never smokers with bronchial asthma

Effects of tiotropium bromide(136310-93-5) (inhaled long-acting muscarinic antagonists) on pulmonary function in current smokers and non-smokers with asthma treated with inhaled corticosteroids (ICS) and other asthma control agents: long-lasting inhalation β2 agonists, leukotriene receptor antagonists and /or theophylline.

We conducted a double-blind, placebo-controlled study of inhaled single-dose tiotropium bromide(136310-93-5) in nine smokers currently smoking and nine asthmatic patients who had never smoked in an intersecting fashion. Pulmonary function was measured before and 1, 3 and 24 hours after inhalation of 18 μg tiotropium bromide(136310-93-5) or placebo. The primary outcome was a change in forced expiratory volume from baseline of 1 second (FEV1), secondary outcome to a change in peak expiratory flow rate (PEFR), and observation of the MathML source.

At baseline, the mean FEV1 for asthma patients with and without a smoking history was 2590 ml and 2220 ml, and the average dose of ICS was taken at 1208 and 1000 μg/day, respectively. In the current smokers and nonsmokers, the increase from baseline FEV1 was 169 ml and 105 ml above placebo 3 h after tiotropium, respectively.

PEFR, tiotropium group and placebo group were significantly higher. Changes in FEVl and PEFR tend to be greater in never smokers than in smokers with current asthma, although there is no statistical difference at any time point.

Tiotropium bromide(136310-93-5) leads to improved lung function and symptoms in both current smokers and non-smokers with asthma. These findings suggest that tiotropium will provide a new strategy for the treatment of bronchial asthma.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved